Literature DB >> 18676885

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

George R Thompson1, Nathan P Wiederhold, Ana C Vallor, Nyria C Villareal, James S Lewis, Thomas F Patterson.   

Abstract

We report a case of Candida glabrata invasive candidiasis that developed reduced susceptibility to caspofungin during prolonged therapy. Pre- and posttreatment isolates were confirmed to be isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed an F659V substitution within the FKS2 region of the glucan synthase complex.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18676885      PMCID： PMC2565919          DOI： 10.1128/AAC.00473-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.

Authors:  René Pelletier; Isabelle Alarie; Réal Lagacé; Thomas J Walsh
Journal:  Med Mycol       Date:  2005-09       Impact factor: 4.076

2.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

3.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Authors:  C M Douglas; J A D'Ippolito; G J Shei; M Meinz; J Onishi; J A Marrinan; W Li; G K Abruzzo; A Flattery; K Bartizal; A Mitchell; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Molecular genotyping of Candida species with special respect to Candida (Torulopsis) glabrata strains by arbitrarily primed PCR.

Authors:  K Becker; D Badehorn; S Deiwick; G Peters; W Fegeler
Journal:  J Med Microbiol       Date:  2000-06       Impact factor: 2.472

6.  Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Authors:  M B Kurtz; G Abruzzo; A Flattery; K Bartizal; J A Marrinan; W Li; J Milligan; K Nollstadt; C M Douglas
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

7.  A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; J A Marrinan; W Li; M B Kurtz
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Identification of Candida spp. by randomly amplified polymorphic DNA analysis and differentiation between Candida albicans and Candida dubliniensis by direct PCR methods.

Authors:  Consuelo Bautista-Muñoz; Xavier M Boldo; Lourdes Villa-Tanaca; César Hernández-Rodríguez
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.

Authors:  Steve Hernandez; José L López-Ribot; Laura K Najvar; Dora I McCarthy; Rosie Bocanegra; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  68 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

3.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

4.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

Authors:  James S Lewis; Nathan P Wiederhold; Brian L Wickes; Thomas F Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

6.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

7.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

8.  Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Cornelia Lass-Flörl; Alicia Gomez Lopez; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

9.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.